Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan-Mar;40(1):166-168.
doi: 10.1016/j.ijmmb.2021.09.010. Epub 2021 Nov 15.

A case with SARS-CoV-2 reinfection from India

Ashok Munivenkatappa  1 , Rima R Sahay  2 , Gururaj R Deshpande  3 , Deepak Y Patil  4 , Anita M Shete  5 , Gajanan N Sapkal  6 , Ravish Kumar  7 , Marappa Narayana  8 , Pragya D Yadav  9 , Vijay Shettar  10
Affiliations
Case Reports

A case with SARS-CoV-2 reinfection from India

Ashok Munivenkatappa et al. Indian J Med Microbiol. 2022 Jan-Mar.

Abstract

A healthcare worker presented with fever, cough, headache and tested positive by SARS-CoV-2 real time reverse transcriptase polymerase chain reaction (qRT-PCR). He got admitted to hospital and recovered after 14 days. After 2 months, as a screening protocol considering the high risk setup he got tested and again found to be positive for SARS-CoV-2 by qRT-PCR. Our patient had detectable levels of Anti-SARS-CoV-2 IgG antibodies during the reinfection but found negative for Neutralizing antibodies (NAb). Our findings suggest that the person after the initial infection might not develop the desired protective immunity to prevent the reinfection as demonstrated by absence of NAb.

Keywords: COVID-19; IgG antibodies; India; Reinfection; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

Figures

Fig. 1
Fig. 1
Graphical presentation of the timeline for the SARS-CoV-2 reinfection. (All the details in the figure are created by author themselves using the licensed version of the online software BioRender.com).
See this image and copyright information in PMC

References

    1. Oster Y., Wolf D.G., Olshtain-Pops K., Rotstein Z., Schwartz C., Benenson S. Proactive screening approach for SARS-CoV-2 among healthcare workers. Clin Microbiol Infect. 2021;27(1):155. doi: 10.1016/S0140-6736(20)30917-X. - DOI - PMC - PubMed
    1. Choudhary M.L., Vipat V., Jadhav S., Basu A., Cherian S., Abraham P., et al. Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India. Indian J Med Res. 2020;151(2 & 3):251–254. doi: 10.4103/ijmr.IJMR_671_20. - DOI - PMC - PubMed
    1. Ella R., Siddharth R., Jogdand H., Sarangi V., Ganneru B., Prasad S., et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. Lancet Infect Dis. 2021;21(7):950–961. doi: 10.1016/S1473-3099(21)00070-0. - DOI - PMC - PubMed
    1. Deshpande G.R., Sapkal G.N., Tilekar B.N., Yadav P.D., Gurav Y., Gaikwad S., et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res. 2020;152(1–2):82. doi: 10.4103/ijmr.IJMR_2382_20. - DOI - PMC - PubMed
    1. Yadav P.D., Nyayanit D.A., Shete A.M., Jain S., Majumdar T.P., Chaubal G.Y., et al. Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to Phlebovirus genus, Family Phenuiviridae. Tick Borne Dis. 2019;10(1):23–33. doi: 10.1016/j.ttbdis.2018.08.012. - DOI - PubMed

Publication types